iShares Core S&P 500 ETF vs Viatris Inc — how do they compare? iShares Core S&P 500 ETF trades at $776.48, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Viatris Inc nearer its low. Which is the better fit depends on your goals.
| IVV | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $776.81 | $17.86 |
52-Week Low | $634.93 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $776.77, up 0.01% with a bullish technical signal from moving averages but overbought RSI readings. The ETF benefits from strong institutional interest, as First Bank & Trust increased its stake by 24.8% in Q2 2026 (SEC filing, August 11, 2026), while Financial Advisory Corp reduced holdings by 3.1%. Market sentiment is mixed amid record highs and inflation concerns, with JPMorgan raising its S&P 500 target to 8,000 (FXEmpire, August 10, 2026).
Outlook remains positive due to robust corporate earnings and AI-driven growth, but risks include high valuations and potential pullbacks. Investors should focus on long-term diversification benefits, with the dividend offering steady income. Key resistance is at $777, with support at $772.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →